Breaking News, Promotions & Moves

Adicet Bio Names Dr. Julia Maltzman as Chief Medical Officer

Maltzman will lead the Adicet clinical development strategy to advance Adicet’s autoimmune and oncology pipeline.

Author Image

By: Charlie Sternberg

Associate Editor

Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has appointed Julie Maltzman, M.D., as Chief Medical Officer, effective January 13, 2025.   Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet’s autoimmune and oncology pipeline.   “We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the clinical deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters